Company Overview and News

2
Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates

2018-08-10 zacks - 1
Abeona Therapeutics (ABEO - Free Report) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.
GD UNIT ABEO ABEOW

1
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights

2018-08-09 globenewswire
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the second quarter of 2018. The Company will host a call to update investors on recent clinical developments and quarter financial results on Friday, August 10th at 10:00 am (Eastern).
ABEO ABEOW

127
Biotech Movers and Shakers for Aug. 6

2018-08-06 biospace - 2
Cellectis – France-based Cellectis named Novartis veteran Stefan Scherto as its new head of clinical development and deputy medical officer. Prior to his role at Cellectis, Scherto served as head of early development of strategy and innovation in U.S. oncology for Novartis. Scherto is expected to play a key role in moving Cellectis’ off-the-shelf gene-edited CAR-T cell product candidates toward commercialization.
ABT ALXN GILD TRVN QSII KITE ABEO ABEOW ABT BCART

10
Biotech Movers and Shakers for July 30

2018-07-30 biospace
Nabriva Therapeutics – Nabriva Therapeutics restructured part of its leadership team in the wake of the acquisition of Zavante Therapeutics. Colin Broom, who had served as chief executive officer of Nabriva, was replaced by Zavante CEO Ted Schroeder. Broom will maintain a seat on the board of directors and serve in an advisory role to Schroeder. Steven Gelone, Nabriva's chief scientific officer and head of business & corporate development, has been named president and chief operating officer of Nabriva.
VYGR OPTI ALXN NBRV ABEO ABEOW ARIA OPBXF

2
Fibrocell Science: An Underappreciated Gene Therapy Play

2018-07-27 seekingalpha
There are clear risks in terms of continued dilution, but we believe these risks are outweighed by the positive data presented from Fibrocell's lead gene therapy program, FCX-007.
FCSC KRYS ABEO ABEOW

32
Rounds Report: Nephros Posts Strong Preliminary Financial Results For Q2

2018-07-13 seekingalpha - 3
The overall bioscience market traded with a mixed sentiment for the day. Nevertheless, many equities under over coverage continued to rally.
NTLA SLDB SGMO CRSP ABEO XBI ONCE RGNX NEPH EDIT ADVM IBB ABEOW

2
Synacor Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
Synacor, Inc. (SYNC - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because SYNC recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT SYNC ABEO ABEOW

1
Old Dominion Freight Line Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
Old Dominion Freight Line, Inc. (ODFL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because ODFL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
ODFL LMT ABEO ABEOW ODLF

4
GMS Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks
GMS Inc. (GMS - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because GMS recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT ABEO ABEOW GMS

3
Pacific Ethanol Sees Hammer Chart Pattern: Time to Buy?

2018-07-12 zacks - 1
Pacific Ethanol, Inc. (PEIX - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because PEIX recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
LMT PEIX ABEO ABEOW

1
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options

2018-07-11 zacks
Investors in Abeona Therapeutics Inc. (ABEO - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $17.50 Call had some of the highest implied volatility of all equity options today.
ABEO ABEOW

69
Editas: The Most Comprehensive CRISPR Platform - But At What Cost?

2018-06-22 seekingalpha - 3
The cost of IP litigation, fees triggered by market cap increases and royalties on all product revenues are not shareholder-friendly.
VYGR BOLD NTLA EDIT CRSP ABEO ABEOW ONCE

77
Voyager: A Leader In Neurological Gene Therapy Receives RMAT Designation

2018-06-22 seekingalpha
The RMAT designation resulted from Phase I b clinical data and is a tool to help expedite programs for serious conditions.
VYGR BOLD NTLA EDIT CRSP ABEO ABEOW PFE ONCE RGNX

143
DCPH / Deciphera Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-21 fintel.io - 1
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has 53 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 15,564,771 shares. Largest shareholders include New Leaf Venture Partners, L.L.C., Viking Global Investors LP, SV Life Sciences Advisers, LLC, Orbimed Advisors Llc, FMR LLC / Fidelity, Redmile Group, LLC, BlackRock Inc.
DCPH PRTO BLK IOVA GALPW ABEO ABEOW GALE MEIP GALEW

81
Gilead Oncology CAR T-Cell Therapies Outlook Compelling

2018-06-18 seekingalpha - 1
If cell therapies are curative, new business models will become more cyclical. Harvoni and Sovaldi cure rates exceeding 90% show Gilead understands this new paradigm.
VYGR BOLD NTLA ATRA EDIT GILD CRSP ABEO ABEOW ONCE

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

CUSIP: 00289Y115